Metronidazole and Peripheral Neuropathy: A Report of Two Cases of (Unusual) Side Effects

Stefano Gussago, Cristiana Poroli Bastone, Diana Celio, Michele Arigoni, Massimo C. Quarenghi

Abstract

Metronidazole is an antibiotic commonly prescribed for anaerobic and protozoan infections. Despite its good safety profile, this drug frequently causes a series of well-known side effects (nausea and intestinal transit disorders, dysgeusia, headaches, and alcohol intolerance). However, there are few data in the literature, mainly case reports and case series, about the onset of peripheral neuropathy with a generally self-limiting course after drug withdrawal. Thus, we herein describe two cases of peripheral neuropathy due to treatment with metronidazole. A 69-year-old woman treated with a total of 55 g of metronidazole for diverticular disease and a 52-year-old male patient on a long course of antibiotic therapy for hepatic abscesses (a cumulative dose of 168 g) developed peripheral neuropathy. The suspicion of metronidazole side effects was raised after the exclusion of other causes. After the suspension of the drug, different degrees of improvement were observed. Metronidazole is an effective antibiotic for treating infections caused by anaerobic or protozoan pathogens, and it has a good pharmacological and economic safety profile. However, in the existing literature, prolonged therapy regimens (>4 weeks of treatment and/or 42 g cumulative dose) may increase the risk of developing neurological complications, in particular peripheral polyneuropathy.

Introduction

In modern medicine, ‘side effect’ is generically defined as any unintended or unwanted (not necessarily harmful) effect linked to the pharmacological action of a therapeutic substance [1]. These events are usually classified based on frequency according to the criteria of the Council for International Organizations of Medical Sciences: very common, common, uncommon, rare, and very rare [2].

In this regard, the most frequent extra neurologic side effects of metronidazole (1-β-hydroxy-ethyl)-2-methyl-5-nitroimidazole), an antibiotic commonly used for anaerobic and protozoan infections, are well known, including nausea and intestinal transit disorders, dysgeusia, headache, and alcohol intolerance (Antabuse effect) [3]. However, the occurrence of neurologic symptoms, particularly peripheral neuropathy that is prevalent in the lower limbs, during prolonged therapy with metronidazole is rarely reported [4,5].

Thus, we present herein two recently identified cases of peripheral neuropathy due to metronidazole treatment. Moreover, we also performed a brief review of the relevant existing literature.

Case Presentation

Clinical case 1

A 69-year-old woman with a generally good condition, who was on chronic steroid therapy for polymyalgia rheumatica and levothyroxine after subtotal thyroidectomy for Graves Basedow disease, presented to our institution due to a recurrence of acute diverticulitis of the sigma complicated by a covered perforation. A computed tomography scan shows a small abscess adjacent to the intermediate sigma (modified Hinchey Ib) that is not appropriate for percutaneous drainage; hence, prolonged antibiotic therapy and subsequent surgical treatment by laparoscopic resection of the sigma were planned. Preoperatively, an antibiotic regime of ciprofloxacin (500 mg 2×/day) and metronidazole (500 mg 3×/day) was administered.

After the laparoscopic resection of the rectum sigma, antibiotic therapy is suspended. The immediate postoperative surgical course takes place without complications, with the rapid resumption of feeding and gastrointestinal transit. However, on day 5 after the surgery, the patient reports the appearance of allodynia and paresthesia in the lower limbs. A more in-depth anamnesis revealed that this symptomatology was already present, although of lesser severity, a few days prior to admission, and the progression of the
disorder has greatly bothered the patient.

On neurological examination, the patient had dysesthesia with a bilaterally moderate pallesthesia, without significant trophic and stenic alterations, and with normoeicitable osteo-tendon reflexes. In particular, the patient has an unstable tightrope walk. No sphincter or urinary disorders were revealed on examination. Electroneurography does not show axonal or myelin abnormalities, consistent with polyneuropathy involving small fibers (Table 1).

| Nerve | Neurography | Stimulus | Registration | Dist. (cm) | Latency (msec) | Answer | NCV (m/s) |
|-------|-------------|----------|--------------|-----------|---------------|--------|-----------|
| Tibial right | Motoric | Internal malleolus | Abd. hallucis | 12 | 5.0 | 12 | |
| | | Popliteal fossa | Abd. hallucis | 39 | 13.0 | 12 | 48 |
| | | F wave | | | | | 46.4 |
| Peroneal right | Motoric | Ankle | Ext. Dig. Brevis | 6.5 | 4.5 | 8 | |
| | | Peroneal neck | Ext. Dig. Brevis | 21 | 8.9 | 8 | 49 |
| | | Popliteal fossa | Ext. Dig. Brevis | 10 | 10.9 | 8 | 49 |
| H Reflex | | | | | | | 29.4 |
| Sural right | Sensitive orthodromic | | | 14 | 2.8 | 4 μV | 50 |

**TABLE 1: Electroneurography of the tibial and right peroneal nerves.**
msec: milliseconds; NCV: nerve conduction velocity.

A preoperative contrast-enhanced abdominal CT scan performed in the context of diverticular disease did not show any abnormalities of the lumbar spine. After ruling out diabetes, use of alcohol, and vitamin deficiency (in particular: cobalamin and folate), we attribute the origin to possible drug toxicity due to metronidazole administration. Reviewing the patient’s medical record, it is clear that during the numerous episodes of diverticulitis and recent conservative treatment, the patient has received a total of 55 g of metronidazole in the last eight weeks.

After metronidazole treatment was discontinued, it was possible in the following months to find a partial remission of the neurological problem with, however, a moderate residual lameness due to persistent hypesthesia of the lower limbs.

**Clinical case 2**
A 52-year-old patient who, following a type A aortic dissection complicated by renal, hepatic, and intestinal ischemia, developed a type III short bowel syndrome [7] with partial dependence on parenteral nutrition, partial liver insufficiency, renal insufficiency, and chronic cholestasis due to a stenosis of the extra- and intrahepatic biliary tracts because of scarring.

The patient developed multiple polymicrobial hepatic abscesses (caused by Enterococcus faecium and Escherichia coli) due to recurrent cholangitis, which required multiple percutaneous drainages and retrograde endoscopic cholangio-pancreatography with biliary stent placement. The abscesses persisted despite repeated treatments; thus, a long-term antibiotic tri-therapy (amoxicillin 750 mg 3 ×/day, metronidazole 500 mg 3 ×/day, and ciprofloxacin 750 mg 2 ×/day) was initiated. After approximately four months of treatment, the patient develops a predominantly sensitive disorder, i.e., paresthesia and allodynia in the distal lower limb (especially the plantar region) and the left forearm with the sensation of pins and painful cramps.

During the consequent hospitalization, a slight motor impairment with disequilibrium and dysarthria was also observed; thus, the patient underwent magnetic resonance imaging (MRI) of the brain and epi-aortic vessels as well as a carotid echo-color-Doppler examination, which both showed negative findings. The most probable etiological hypothesis of the neurological symptoms seems to be related to a toxic–metabolic genesis; thus, further investigations for possible vitamin deficiencies (in particular: cobalamin, thiamine pyrophosphate, and pyridoxal-5-phosphate) or metal poisoning (e.g., copper, lead, and mercury) were performed, but no abnormalities were found (Table 2).
### TABLE 2: Main biochemical investigations.

| Test                              | Value | Reference  | Unit of measure |
|-----------------------------------|-------|------------|-----------------|
| Copper                            | 14.6  | 11.0–22.0  | µmol/L          |
| Zinc                              | 7.4   | 12.0–26.0  | µmol/L          |
| Selenium                          | 0.76  | 0.64–1.52  | µmol/L          |
| Aluminum                          | 0.30  | <0.37      | µmol/L          |
| Lead                              | 6     | <10        | nmol/L          |
| Thiamine pyrophosphate            | 94    | 67–200     | nmol/L          |
| Pyridoxal-5-phosphate             | 103   | 35–110     | nmol/L          |
| Cobalamin                         | 439   | 145–569    | pmol/L          |
| Folic acid                        | 34.8  | 8.8–60.8   | nmol/L          |
| Anti-nuclear antibodies IF        | 1/80  | <1/80      | -               |
| Anti-neutrophil cytoplasmic antibodies | <1/80 | <1/80      | -               |
| Anti-extractable nuclear antigen screen | Negative | Negative | -               |
| Anti-neutrophil cytoplasmic antibodies IF | <1/10 | <1/10      | -               |
| Rheumatoid factor                 | 11.3  | <15.0      | U/mL            |
| Anti-citrulline antibodies        | 0.8   | <7–10      | U/mL            |
| Anti-neuronal antibodies (Hu, Ri) | <1/80 | <1/80      | -               |
| Anti-Purkinje antibodies (Yo)     | <1/80 | <1/80      | -               |
| HIV antigen P-24                  | Negative | Negative | -               |
| HIV IgG                           | Negative | Negative | -               |
| HCV antibodies                    | Negative | Negative | -               |
| Borrelia Burgdorferi IgG          | 0.14  | <0.20      | -               |
| Borrelia Burgdorferi IgM          | 0.0   | <0.2–0.32  | -               |
| Treponema Pallidum Ig             | Negative | Negative | -               |

IF, immunofluorescence; HIV, human immunodeficiency virus; HCV, hepatitis C virus; IgG, immunoglobulin G; IgM, immunoglobulin M; Ig, immunoglobulin.

The diagnostic hypothesis, therefore, focuses on the potential toxic action of metronidazole; thus, after consulting with an infectious disease specialist, the metronidazole was suspended given the regression of liver abscesses on control MRI. Electromyoneurography revealed a moderate axonal sensorimotor-type polyneuropathy, consistent with a prolonged latency and smaller nerve conduction velocity, prevalent in the lower limbs (Tables 3–5).
### TABLE 3: Electroneuromyography revealed a moderate axonal sensorimotor-type polyneuropathy, prevalent in the lower limbs.

msec, milliseconds; NCV, nerve conduction velocity.

| Nerve       | Neurography | Stimulus       | Registration       | Distance (cm) | Latency (msec) | Potential (mV) | Duration (msec) | NCV (m/s) |
|-------------|-------------|----------------|--------------------|---------------|----------------|----------------|----------------|-----------|
| Tibial right| Motoric     | Abd. hallucis  | Ankle              | 10.5          | 6.9            | 2.2            | 5.9            |           |
|             |             | Ankle          | Popliteal fossa    | 44.0          | 19.2           | 1.8            | 9.7            | 36        |
| Peroneal right| Motoric   | Ext. Dig. Brevis| Ankle              | 7.5           | 6.7            | 3.0            | 5.9            |           |
|             |             | Ankle          | Peroneal (head)    | 31.0          | 15.1           | 3.1            | 6.4            | 37        |
| Tibial left | Motoric     | Abd. hallucis  | Ankle              | 8.0           | 18.0           | 2.8            | 6.4            | 28        |
|             |             | Ankle          | Popliteal fossa    | 20.5          | 6.5            | 2.1            | 5.9            |           |
| Peroneal left| Motoric    | Ext. Dig. Brevis| Ankle              | 46.0          | 19.7           | 2.1            | 6.4            | 34        |
|             |             | Ankle          | Peroneal (head)    | 7.5           | 5.5            | 2.6            | 7.2            |           |
|             |             | Ankle          | Peroneal (head)    | 35.0          | 15.9           | 1.9            | 7.7            | 34        |
|             |             | Ankle          | Popliteal fossa    | 10.0          | 17.9           | 2.1            | 7.8            | 50        |
| Ulnar right | Motoric     | Abductor digiti minimi | Wrist            | 7.5           | 3.2            | 7.3            | 7.0            |           |
|             |             | Wrist          | Distal solcus      | 26.0          | 8.3            | 7.2            | 6.9            | 51        |
|             |             | Distal solcus  | Proximal solcus    | 20.0          | 10.5           | 6.6            | 7.7            | 45        |
| Sural right | Sensitive   |                |                    |               |                |                |                |           |
| Sural left  | Sensitive   |                |                    |               |                |                |                |           |
| Ulnar right | Sensitive   |                |                    |               |                |                |                |           |

### TABLE 4: Needle electromyography.

| Measurement site       | Insertion | Spontaneous activity | Voluntary activity | Maximum effort |
|------------------------|-----------|----------------------|--------------------|----------------|
| Gastrocnemius medial right | Duration | Positive waves     | Fibrillation       | Fasculation    | Amplitude     | Duration | Polyphasic | Trace | Effort  |
|                        |           | -                    | -                  | -              | Increased     | Normal    | Normal     | Absent |         |

2022 Gussago et al. Cureus 14(10): e30889. DOI 10.7759/cureus.30889
To determine the etiology, we also performed an investigation on auto-antibodies [antinuclear antibodies, extractable nuclear antigen, anti-neutrophil cytoplasmic antibodies, anti-citrulline, rheumatoid factor, anti-neuronal antibodies (Hu, Ri), and anti-Purkinje (YO)] and antibodies for HIV, hepatitis C virus, Borrelia burgdorferi, and Treponema pallidum, which showed no abnormal results (Table 2).

The patient had rapid improvement of dysarthria (one week) after discontinuation of antibiotic therapy with metronidazole. Moreover, progressive improvement of the peripheral neuropathy was observed, despite the presence of residual bilateral stocking hypoesthesia of the lower limbs and the distal phalanges of both hands, at <4 months after the suspension of therapy.

Discussion

In the existing literature [4,5,8], the appearance of peripheral neuropathy is described as among the potential side effects of metronidazole, but its exact prevalence and cumulative doses are not well established. Neither a clear pathophysiological mechanism of peripheral neuropathy related to metronidazole is established, although some role seems to be played by the toxicity of its metabolites [5].

We report two cases of peripheral neuropathy that, after extensive etiological investigation, were attributed to a side effect of metronidazole occurring in two patients with very different manifestations: a woman without a marked medical history and a man with hepato-renal insufficiency. Peripheral neuropathy, as shown by the two electroneuromyography studies (Tables 1-3), can be attributed to different mechanisms. In case 1, the patient presents with an isolated peripheral neuropathy resulting probably from damage involving the small fibers, such as the case has been described in previous case reports [4], whereas case 2 presents a mixed disorder with both central (considering the dysarthria) and peripheral symptoms. In this latter, the patient had a symmetric moderate axonal sensorimotor-type polyneuropathy documented at the electromyoneurography. These findings are consistent with previous literature, where metronidazole-induced paresthesia is linked to predominant small fiber involvement, although, to a lesser extent, large fibers may also be involved [9]. Interestingly, despite the involvement of the central nervous system, the second patient had normal MRI findings with no evidence of cerebellar abnormalities, as described in some case reports [10,11].

In 2013, in a randomized trial conducted by Carroll et al. to evaluate the efficacy of oral metronidazole therapy (500 mg 3 ×/day) for tuberculosis pneumonia caused by multi-resistant germs, the therapy was suspended in advance owing to a 4.3-fold higher risk of developing peripheral neuropathies after six months of treatment in the treatment group (almost 50% of patients) than in the placebo arm [12].

In 2010, the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America, which provided the guidelines for treating Clostridium difficile infections (grade IIB), recommended that metronidazole should not be used to treat recurrences or as a long-term treatment owing to the risk of developing cumulative neurotoxicity [13].

The recent review by Goolsby et al. in 2018 [5], which included 13 clinical studies and >36 case reports, described that the actual incidence of this side effect in patients receiving treatment with metronidazole is still controversial, with the studies showing extremely wide variations (0-50%). However, this complication appears to be associated with prolonged therapy, i.e., generally >4 weeks and with a cumulative metronidazole dose >42 g, with the risk of developing peripheral neuropathy during metronidazole treatment rising from 1.7% to 17.9% in the latter subgroup [5]. The cumulative dose of case 1 was 55 g within eight weeks of treatment and that of case 2 was approximately 168 g within 16 weeks of treatment before the first symptoms of neuropathy appeared. On the other hand, Daneman et al. found no correlation between the cumulative dose and the occurrence of neuropathy [14].

It, therefore, remains imperative to suspend treatment with metronidazole in the event of suspected peripheral neuropathy. Moreover, evidence from the literature indicates that a restitutio ad integrum is
often obtained, even if the timing for complete resolution, if reached, is very variable (from 2 weeks to 1.5 years) [5]. In case 1, improvement of the neuropathy symptoms improved two months after treatment suspension, whereas in case 2, partial regression of symptoms was observed at four months after treatment suspension, although residual acral hypoesthesia in the lower limbs still persisted.

Although the abovementioned evidence may discourage the use of metronidazole, we must remember that, generally, this drug is well tolerated; in monotherapy and in regimens of poly antibiotic therapy, the cumulative dose is lower than that considered risky in the literature. A classic therapy of 7-10 days as indicated, for example, in the case of uncomplicated diverticulitis [15], results in a cumulative dose of 14-20 g, which is well below the dose reported by Goolsby et al. in their review [5].

Furthermore, the spectrum of anti-anaerobic antimicrobial activity makes metronidazole a good drug for controlling diseases such as intra-abdominal infections [3], for which the therapeutic alternatives are generally more expensive, and whose abuse could lead to an increase in bacteriological resistance.

Conclusions

Metronidazole is an effective antibiotic for treating infections caused by anaerobic or protozoan pathogens, and it has a good pharmacological and economic safety profile. However, in the existing literature, prolonged therapy regimens (>4 weeks of treatment and 42 g cumulative dose) may increase the risk of developing neurological complications, in particular peripheral polyneuropathy. Thus, it is advisable that, if a prolonged therapeutic regimen is prescribed, the appearance of peripheral neurological symptoms should be monitored; if such cases occur, it is mandatory to suspend the therapy. In patients with peripheral neurological symptoms, the prognosis is generally favorable with complete remission of the symptomatology in the majority of cases after treatment suspension, although, in the literature, the timing for a restitutio ad integrum results extremely varies.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors thank Dr Eduard Portell Penadés for critically reviewing the electromyoneurography study interpretation.

References

1. World Health Organization, Glossary. (2018). Accessed: September 26, 2022: https://www.who.int/glossary.
2. Council for International Organizations of Medical Sciences (CIOMS): Guidelines for Preparing Core Clinical-Safety information on Drugs, Second Edition, Report of CIOMS Groups III and V. CIOMS (ed): CIOMS, Geneva; 1999. https://cioms.ch/wp-content/uploads/2018/03/Guidelines-for-Preparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMS.....
3. Ceruelos AH, Romero-Quezada LC, Ledezma JR, Contreras LL: Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci. 2019, 23:397-401.
4. Sarna JR, Furtado S, Brownell AK: Neurologic complications of metronidazole. Can J Neurol Sci. 2013, 40:768-76. 10.1017/s0317167100015850
5. Goolsby TA, Jakeman B, Gaynes RP: Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents. 2018, 51:119-25. 10.1016/j.ijantimicag.2017.08.035
6. Sher ME, Agachan F, Burtol M, Nogueras JI, Weiss EG, Wexner SD: Laparoscopic surgery for diverticulitis. Surg Endosc. 1997, 11:264-7. 10.1007/s004649900340
7. Pirzio L, Arends J, Baxter J, et al.: ESPEN-endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015, 34:171-80. 10.1016/j.clnu.2014.08.017
8. Flagyl® metronidazole tablets. (2013). Accessed: September 26, 2022: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020334s008lbl.pdf.
9. Zivkovic SA, Lacomis D, Giuliani MJ: Sensory neuropathy associated with metronidazole: report of four cases and review of the literature. J Clin Neuromuscul Dis. 2001, 3:8-12. 10.1097/00131402-200109000-00002
10. Sarna JR, Brownell AK, Furtado S: Cases: reversible cerebellar syndrome caused by metronidazole. CMAJ. 2009, 181:611-3. 10.1503/cmaj.090591
11. Agarwal A, Kanekar S, Sabat S, Thamburaj K: Metronidazole-induced cerebellar toxicity. Neurol Int. 2016, 8:6565. 10.4081/ni.2016.6565
12. Carroll MW, Jeon D, Mountz JM, et al.: Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2015, 57:3903-9. 10.1128/AAC.00753-13

13. Cohen SH, Gerding DN, Johnson S, et al.: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010, 31:431-55. 10.1086/651706

14. Daneman N, Cheng Y, Gomes T, Guan J, Mamdani MM, Saxena FE, Juurlink DN: Metronidazole-associated neurologic events: a nested case-control study. Clin Infect Dis. 2021, 72:2095-100. 10.1093/cid/ciaa395

15. Gilbert DN, Chambers HF, Eliopoulos GM, et al.: The Sanford Guide to Antimicrobial Therapy 2019 (49th Edition). Antimicrobial Therapy, Inc., Sperryville; 2019.